lansoprazole has been researched along with dexlansoprazole in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (44.44) | 29.6817 |
| 2010's | 27 (50.00) | 24.3611 |
| 2020's | 3 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bi, Y; Kuberan, B; Might, M; Vankayalapati, H | 1 |
| Chen, WL; Chen, X; Guo, XK; Jiang, ZY; Li, DD; Wang, YZ; Xu, JJ; You, QD | 1 |
| Cha, IJ; Hyun, MH; Kim, KA; Kim, MJ; Kim, MK; Park, JY; Shin, JG; Shon, JH; Yoon, YR; Yun, DH | 1 |
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 3 |
| Cha, IJ; Jung, WM; Kang, W; Kim, MJ; Liu, KH; Shin, JG | 1 |
| Cha, IJ; Kang, W; Kim, MJ; Liu, KH; Moon, YS; Seol, SY; Shin, JG; Shon, JH | 1 |
| Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Kagaya, H; Miura, M; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Miura, M | 1 |
| Habuchi, T; Inoue, K; Ishikawa, M; Kagaya, H; Kanno, S; Miura, M; Sagae, Y; Saito, M; Satoh, S; Suzuki, T; Tada, H | 1 |
| Hayakari, M; Miura, M; Niioka, T; Suzuki, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Ang, TL; Fock, KM | 1 |
| Gunawardhana, L; Lee, RD; Mulford, D; Vakily, M; Wu, J | 1 |
| Atkinson, SN; Lee, M; Perez, MC; Peura, D; Pilmer, BL; Shaheen, NJ; Sharma, P | 1 |
| Atkinson, SN; Howden, CW; Larsen, L; Metz, DC; O'Neil, J; Perez, MC | 1 |
| Atkinson, SN; Mulford, D; Vakily, M; Wu, J; Zhang, W | 1 |
| Atkinson, SN; Lee, RD; Mulford, D; Vakily, M; Wu, J | 1 |
| Dixit, T; Metz, DC; Mulford, D; Vakily, M | 1 |
| Atkinson, SN; Wu, J; Zhang, W | 1 |
| Atkinson, SN; Howden, CW; Larsen, LM; Palmer, R; Perez, MC | 1 |
| Aslam, N; Wright, R | 1 |
| Atkinson, SN; Dabholkar, AH; Metz, DC; Paris, MM; Peura, DA; Yu, P | 1 |
| Atkinson, SN; Vakily, M; Wu, J | 1 |
| Atkinson, SN; Lee, RD; Mulford, D; Wu, J | 1 |
| Harnam, N; Larsen, LM; Lee, M; Mody, R; Revicki, DA; Wyrwich, KW | 1 |
| Abel, C; Desilets, AR; Willett, K | 1 |
| Davies, SL | 1 |
| Croxtall, JD; Scott, LJ | 1 |
| Emerson, CR; Marzella, N | 1 |
| Atkinson, SN; Dabholkar, AH; Han, C; Paris, MM; Perez, MC; Peura, DA | 1 |
| Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN | 1 |
| Fass, R; Hershcovici, T; Jha, LK | 1 |
| Hotha, KK; Jagadeesh, B; Jaya Veera, KN; Ravindranath, LK; Venkateswarulu, V; Vijaya Bharathi, D | 1 |
| Kukulka, M; Perez, MC; Wu, J | 1 |
| Behm, BW; Peura, DA | 1 |
| Han, C; Metz, DC; Perez, MC; Pilmer, BL | 1 |
| Fass, R; Han, C; Inadomi, J; Mody, R; O'Neil, J; Perez, MC | 1 |
| Grabowski, B; Lee, RD | 1 |
| Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B | 2 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Choi, Y; Chung, HK; Kang, JS; Kim, KH; Mai, XL; Mar, W; Truong, QK | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Grady, H; Kukulka, M; Mulford, D; Murakawa, Y | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Chang, TE; Hou, MC; Huang, YH; Lee, FY; Lin, XH; Luo, JC; Ting, PH | 1 |
| Lespessailles, E; Toumi, H | 1 |
14 review(s) available for lansoprazole and dexlansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2006 |
Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Chemistry, Pharmaceutical; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexlansoprazole; Drug Industry; Esophagitis, Peptic; Humans; Lansoprazole; Patents as Topic; Proton Pump Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2008 |
Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Humans; Lansoprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2009 |
Dexlansoprazole MR.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansoprazole; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors; Treatment Outcome | 2009 |
Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Drug Interactions; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors; Treatment Outcome | 2010 |
Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansoprazole; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors | 2010 |
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Delayed-Action Preparations; Dexlansoprazole; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Proton Pump Inhibitors; Treatment Outcome | 2010 |
Dexlansoprazole MR: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Dexlansoprazole; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Mucous Membrane; Proton Pump Inhibitors; Stereoisomerism | 2011 |
Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansoprazole; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Treatment Outcome; United States | 2011 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
Topics: Capsules; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dexlansoprazole; Humans; Intestine, Small; Lansoprazole; Proton Pump Inhibitors | 2019 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
25 trial(s) available for lansoprazole and dexlansoprazole
| Article | Year |
|---|---|
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Half-Life; Humans; Korea; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Stereoisomerism | 2002 |
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Time Factors | 2004 |
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Genotype; Heterozygote; Homozygote; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism | 2005 |
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus | 2005 |
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Beverages; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Humans; Intestines; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Stereoisomerism | 2006 |
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alleles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Gastroesophageal Reflux; Genotype; Half-Life; Humans; Immunosuppressive Agents; Japan; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Organic Anion Transporters; Polymorphism, Genetic; Tacrolimus | 2006 |
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexlansoprazole; Double-Blind Method; Female; Fluvoxamine; Genotype; Half-Life; Humans; Lansoprazole; Male; Models, Biological; Proton Pump Inhibitors; Stereoisomerism | 2008 |
Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anticoagulants; Anticonvulsants; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Diazepam; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Phenytoin; Proton Pump Inhibitors; Theophylline; Warfarin; Young Adult | 2009 |
Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Dexlansoprazole; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2009 |
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Dexlansoprazole; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis; Female; Gastric Mucosa; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Patient Satisfaction; Proton Pump Inhibitors; Quality of Life; Secondary Prevention; Treatment Outcome | 2009 |
Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Dietary Fats; Fasting; Female; Food-Drug Interactions; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Young Adult | 2009 |
Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Dose-Response Relationship, Drug; Female; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors | 2009 |
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2009 |
Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Electrocardiography; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Statistics as Topic; Young Adult | 2009 |
The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer Agents; Dexlansoprazole; Diet Records; Esophagitis, Peptic; Female; Health Status; Humans; Lansoprazole; Male; Medical Records; Middle Aged; Proton Pump Inhibitors; Psychometrics; Quality of Life; Reproducibility of Results; Severity of Illness Index; Statistics as Topic; Statistics, Nonparametric; Surveys and Questionnaires | 2010 |
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Delayed-Action Preparations; Dexlansoprazole; Dose-Response Relationship, Drug; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Statistics as Topic; Time Factors; Treatment Outcome; Young Adult | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Blind Method; Drug Administration Schedule; Efficiency; Female; Gastroesophageal Reflux; Health Status; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Quality of Life; Risk Factors; Severity of Illness Index; Sleep Wake Disorders; Surveys and Questionnaires; Treatment Outcome | 2011 |
Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Area Under Curve; Child; Dexlansoprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Proton Pump Inhibitors | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Quality of Life; Single-Blind Method; Treatment Outcome; Young Adult | 2012 |
Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Carbon Radioisotopes; Cytochrome P-450 CYP2C19; Delayed-Action Preparations; Dexlansoprazole; Drug Delivery Systems; Genotype; Humans; Lansoprazole; Male; Middle Aged; Oxidation-Reduction; Proton Pump Inhibitors; Young Adult | 2012 |
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult | 2012 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2013 |
Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Topics: Aged; Cough; Dexlansoprazole; Dyslipidemias; Esophagitis; Female; Gastroesophageal Reflux; Globus Sensation; Hoarseness; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2020 |
15 other study(ies) available for lansoprazole and dexlansoprazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Genetic Diseases, Inborn; Humans; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Molecular Structure; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone-Lysine N-Methyltransferase; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Molecular Structure; Myeloid-Lymphoid Leukemia Protein; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship | 2020 |
Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2C9; Dexlansoprazole; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism; Substrate Specificity | 2005 |
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexlansoprazole; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism | 2005 |
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Area Under Curve; Dexlansoprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2009 |
Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Delayed-Action Preparations; Dexlansoprazole; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors; Treatment Outcome | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dexlansoprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2009 |
Dexlansoprazole for the treatment of esophagitis and GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Child; Clinical Trials as Topic; Dexlansoprazole; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors | 2010 |
Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Chromatography, Liquid; Dexlansoprazole; Drug Stability; Humans; Lansoprazole; Linear Models; Liquid-Liquid Extraction; Male; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dexlansoprazole; Esophagitis; Female; Gastric Acid; Gastrins; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Withholding Treatment | 2011 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Clinical Trials as Topic; Dexlansoprazole; Dose-Response Relationship, Drug; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Risk Factors; Severity of Illness Index; Treatment Outcome; Young Adult | 2013 |
Determination of S-(-)-lansoprazole in dexlansoprazole preparation by capillary zone electrophoresis.
Topics: beta-Cyclodextrins; Dexlansoprazole; Electrophoresis, Capillary; Lansoprazole; Limit of Detection; Proton Pump Inhibitors; Stereoisomerism | 2017 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |